News

Biden Authorizes FEMA To Provide COVID-19 Response Assistance

-Bloomberg

byBill Haddad

December 27, 2021

1 minute read

-Bloomberg

LivaNova Reports Patient Implanted In OSPREY Study For Patients Coping With Obstructive Sleep Apnea

By Benzinga Newsdesk

Today, 7:54 AM

Study to evaluate effectiveness of hypoglossal nerve stimulation LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced the first patient

LIVN

Citius Pharmaceuticals Q1 EPS $(0.02) Up From $(0.06) YoY

By Michael Horton

Today, 7:54 AM

Citius Pharmaceuticals (NASDAQ:CTXR) reported quarterly losses of $(0.02) per share. This is a 66.67 percent increase over losses of $(0.06) per share from the same period last year.

CTXR

Morgan Stanley Cuts Rivian Price Target: EV Maker Needs To Restore Confidence It Can Be ‘The One’ To Challenge Tesla

By Rachit Vats

Today, 7:54 AM

Rivian Automotive Inc (NASDAQ: RIVN) is facing a new reality after its blockbuster listing last year and needs to ‘pace itself’ in the near term to be able to reinforce confidence that it has the potential to be "the one" that can challenge Tesla Inc (NASDAQ:

RIVN

Intellia Therapeutics To Present Updated Interim Clinical Data From Ongoing Phase 1/2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2022 ACAAI Annual Scientific Meeting

By Benzinga Newsdesk

Today, 7:54 AM

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced that an abstract

NTLA

Biden Authorizes FEMA To Provide COVID-19 Response Assistance

Related Posts

LivaNova Reports Patient Implanted In OSPREY Study For Patients Coping With Obstructive Sleep Apnea

Citius Pharmaceuticals Q1 EPS $(0.02) Up From $(0.06) YoY

Morgan Stanley Cuts Rivian Price Target: EV Maker Needs To Restore Confidence It Can Be ‘The One’ To Challenge Tesla

Intellia Therapeutics To Present Updated Interim Clinical Data From Ongoing Phase 1/2 Study Of NTLA-2002 For The Treatment Of Hereditary Angioedema At The 2022 ACAAI Annual Scientific Meeting